Cellectis (NASDAQ:CLLS) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Open	$1.59
Close	$1.67
Volume / Avg.	331.28K / 138.12K
Day Range	$1.53 - $1.72
52 Wk Range	1.41 - 3.38
Market Cap	$158.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	0.25%
Days to Cover	1.28

Recent News

Cellectis Upgraded to Buy: Here's Why

Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

Zacks

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

Lisa Levin

Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting determination.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.59
Close	$1.67
Volume / Avg.	331.28K / 138.12K
Day Range	$1.53 - $1.72
52 Wk Range	1.41 - 3.38
Market Cap	$158.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	0.25%
Days to Cover	1.28

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cellectis (CLLS) stock?

You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.

View our list of the best stock brokerages

Who are Cellectis (CLLS) competitors?

Other companies in Cellectis’s space includes: Renovaro (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Zentalis Pharma (NASDAQ:ZNTL), Fate Therapeutics (NASDAQ:FATE) and Adaptimmune Therapeutics (NASDAQ:ADAP).

What is the forecast, or price target, for Cellectis (CLLS) stock?

Cellectis has a consensus price target of $7.80.

What is the current price for Cellectis (CLLS)?

The stock price for Cellectis (NASDAQ: CLLS) is $1.58 last updated January 24, 2025 at 9:25 AM EST.

Does Cellectis (CLLS) pay a dividend?

There are no upcoming dividends for Cellectis.

When is Cellectis (NASDAQ:CLLS) reporting earnings?

Cellectis’s Q3 earnings are confirmed for Monday, November 4, 2024.

Is Cellectis (CLLS) going to split?

There is no upcoming split for Cellectis.

What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Cellectis

Cellectis (CLLS) Forecast